These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study. Eppenga WL; Lalmohamed A; Geerts AF; Derijks HJ; Wensing M; Egberts A; De Smet PA; de Vries F Diabetes Care; 2014 Aug; 37(8):2218-24. PubMed ID: 24842984 [TBL] [Abstract][Full Text] [Related]
23. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Salpeter S; Greyber E; Pasternak G; Salpeter E Cochrane Database Syst Rev; 2002; (2):CD002967. PubMed ID: 12076461 [TBL] [Abstract][Full Text] [Related]
24. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
25. Lactate levels in Asian patients with type 2 diabetes mellitus on metformin and its association with dose of metformin and renal function. Lim VC; Sum CF; Chan ES; Yeoh LY; Lee YM; Lim SC Int J Clin Pract; 2007 Nov; 61(11):1829-33. PubMed ID: 17887995 [TBL] [Abstract][Full Text] [Related]
27. Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients. Hanatani T; Sai K; Tohkin M; Segawa K; Saito Y Int J Clin Pharm; 2015 Jun; 37(3):537-45. PubMed ID: 25822043 [TBL] [Abstract][Full Text] [Related]
28. The safety and pharmacokinetics of metformin in patients with chronic liver disease. Smith FC; Stocker SL; Danta M; Carland JE; Kumar SS; Liu Z; Greenfield JR; Braithwaite HE; Cheng TS; Graham GG; Williams KM; Day RO Aliment Pharmacol Ther; 2020 Mar; 51(5):565-575. PubMed ID: 31960986 [TBL] [Abstract][Full Text] [Related]
29. Contraindications can damage your health--is metformin a case in point? Holstein A; Stumvoll M Diabetologia; 2005 Dec; 48(12):2454-9. PubMed ID: 16283245 [TBL] [Abstract][Full Text] [Related]
30. Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study. Connelly PJ; Lonergan M; Soto-Pedre E; Donnelly L; Zhou K; Pearson ER Diabetes Obes Metab; 2017 Nov; 19(11):1579-1586. PubMed ID: 28432751 [TBL] [Abstract][Full Text] [Related]
35. [Traditional contraindications to the use of metformin -- more harmful than beneficial?]. Holstein A; Egberts EH Dtsch Med Wochenschr; 2006 Jan; 131(3):105-10. PubMed ID: 16418951 [TBL] [Abstract][Full Text] [Related]
36. Safety of metformin in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus. Hitchings AW; Archer JR; Srivastava SA; Baker EH COPD; 2015 Apr; 12(2):126-31. PubMed ID: 25938184 [TBL] [Abstract][Full Text] [Related]
37. Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. Hong Y; Rohatagi S; Habtemariam B; Walker JR; Schwartz SL; Mager DE J Clin Pharmacol; 2008 Jun; 48(6):696-707. PubMed ID: 18372428 [TBL] [Abstract][Full Text] [Related]
38. [How I treat ... with metformin a diabetic patient with moderate renal insufficiency]. Scheen AJ Rev Med Liege; 2013 Apr; 68(4):190-5. PubMed ID: 23755710 [TBL] [Abstract][Full Text] [Related]
39. [Safety of metformin in the treatment of elderly type 2 diabetes mellitus]. Tian H; Li CL; Yang G; Wang YZ; Zong WY; Shao YH; Yan ST; Li J; Huang JH; Gong YP; Liu MY Zhonghua Nei Ke Za Zhi; 2008 Nov; 47(11):914-8. PubMed ID: 19080232 [TBL] [Abstract][Full Text] [Related]
40. Metformin therapy in patients with chronic kidney disease. Duong JK; Roberts DM; Furlong TJ; Kumar SS; Greenfield JR; Kirkpatrick CM; Graham GG; Williams KM; Day RO Diabetes Obes Metab; 2012 Oct; 14(10):963-5. PubMed ID: 22564555 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]